Navigation Links
Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
Date:9/19/2011

CRANBURY, N.J., Sept. 19, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2011 financial results on Thursday, September 22, 2011 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 22, 2011, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / WebcastQ4 & Fiscal Year 2011 Financial Results Press Release

9/22/2011 at 7:30 a.m. ETQ4 & Fiscal Year 2011 Conference Call-Live

9/22/2011 at 11:00 a.m. ETDomestic Dial-In Number

1-800-281-7970International Dial-In Number

1-913-312-0671Pass code

9488233Q4 & Fiscal Year 2011 Conference Call-Replay

9/22-9/29/2011Domestic Dial-In Number

1-888-203-1112International Dial-In Number

1-719-457-0820Pass code

9488233Webcast Live and Replay Access

http://www.palatin.com The webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts”
section of Palatin’s website at http://www.palatin.com About Palatin Technologies, Inc.Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Cambridge Semantics was one of just 22 companies ... Capitol Hill, hosted by The Data Transparency ... showcase how innovative data management applications can address the requirements ... , Originally introduced in 2011 by Committee Chairman ... Warner (D-VA ), the DATA Act is designed to ...
(Date:5/22/2013)... SEABROOK, N.H. , May 22, 2013 /PRNewswire/ ... of the Year 2013" by Business NH Magazine.  ... recognized Granite State organizations that distinguish themselves with ... are very proud to receive this honor," said ... Superior Controls.  "As with any recognition, this award ...
(Date:5/22/2013)... Ontario (PRWEB) May 22, 2013 ... advanced sound therapy for tinnitus treatment. AudioNotch is ... Hearing . With clinic locations in both British ... provider of audiology and hearing services. AudioNotch's tinnitus ... locations. , Upon entering a Destination Hearing clinic, ...
(Date:5/22/2013)... Envera announced today that Michael McErlean has ... has an extensive background in cell production and served ... , Mike Matheny, President and Owner of ... join our team”. “Mike’s background is perfectly suited to ... and downstream processing equipment”, added Matheny. “Mike’s hands on ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Envera Appoints Michael McErlean Fermentation Manager 2
... ST. PAUL, Minn., Jan. 3 /Xinhua-PRNewswire/ --,WuXi ... provider of pharmaceutical R&D,outsourcing services, has signed ... Services, Inc. (AppTec). The acquisition of AppTec ... and expertise,gain a significant U.S. operational footprint, ...
... Pharmos Corporation,(Nasdaq: PARS ) announced today ... private placement of its 10% Convertible Debentures due ... $4,000,000 principal amount of the,Debentures, at par, and ... The purchasers consisted of certain existing investors in ...
... Jan. 3 TAP Pharmaceutical Products,Inc. today announced the ... Food and Drug Administration (FDA) for the use of ... and maintenance of,patients with erosive esophagitis and non-erosive reflux ... novel delivery system., "This compound and its novel ...
Cached Biology Technology:WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 2WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 3WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 4WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 5Pharmos Corporation Completes Initial Closing of Private Placement 2
(Date:5/21/2013)... of Illinois at Chicago College of Medicine will study gender ... its main energy source -- and how changes in fat ... $2 million, 4-year grant from the National Heart, Lung and ... uses fuel for energy. These changes may play a major ... in men and women, says E. Douglas Lewandowski, director of ...
(Date:5/21/2013)... Chemical Society (ACS), the world,s largest scientific society, ... Meeting & Exposition, September 8-12, 2013, in Indianapolis, ... Convention Center and at area hotels. , With ... span science,s horizons from astronomy to zoology ... online journalists a rich assortment of spot news ...
(Date:5/21/2013)... experts , Where? Copenhagen, Denmark: Bella ... June 2013 , Why? An ... and policy developments, manufacturing and installation, drawing on leading ... its 2013 edition from a record of more than ... than 240 plenary and oral presentations, more than 460 ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... of Engineering and Applied Science have developed a way ... "greener" fuel alternative to diesel and gasoline from ... current production methods. The findings, ... Microbiology , mark an important advance in the production ...
... 17, 2010 -- University of Miami (UM) Rosenstiel School of ... a new tool to monitor coral reef vital signs. By ... climate change and other ecological threats impact coral reef health ... March 2009 experiment at Cayo Enrique Reef in Puerto Rico, ...
... you have time to quickly swipe your pager or cell phone ... of most of the bacteria. And a simple tissue moistened with ... for a single swipe of a ,dirty, phone you,d be ... highlights of a recently published research study that appeared online in ...
Cached Biology News:UCLA researchers engineer E. coli to produce record-setting amounts of alternative fuel 2Study provides new tool to monitor coral reef 'vital signs' 2Bacterial wipes research study 2
Nestin, Human...
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
Biology Products: